April 3, 2020
Gained Rights to Product Candidate, CZN001 (renamed HZN-825), a Potential Treatment for Diffuse Cutaneous Systemic Sclerosis; a Rare Rheumatic Disease with No FDA-Approved Treatment Compelling Fit with Horizon’s Strategy to Acquire and Develop Medicines Targeting Diseases with High Unmet Need with Focus on Its Core Therapeutic Areas DUBLIN, (BUSINESS WIRE), Apr. 2, 2020 – Horizon...


Denmark Gets Its First Master’s Degree Programme in Neuroscience
4. June 2020
Surge in new alcohol genes
2. June 2020
Video: Meet five professors who have devoted their brains to helping ours
14. May 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge